Hybrid closed-loop systems for the treatment of type 1 diabetes : a collaborative, expert group position statement for clinical use in Central and Eastern Europe

Janež, Andrej (avtor), Battelino, Tadej (avtor), Klupa, Tomasz Klupa (avtor), Kocsis, Győző (avtor), Kuricová, Miriam (avtor), Lalić, Nebojsa M. (avtor), Pantea Stoian, Anca (avtor), Prázný, Martin (avtor), Rahelić, Dario (avtor), Šoupal, Jan (avtor), Tankova, Tsvetalina (avtor), Zelinska, Nataliya (avtor)

In both pediatric and adult populations with type 1 diabetes (T1D), technologies such as continuous subcutaneous insulin infusion (CSII), continuous glucose monitoring (CGM), or sensor-augmented pumps (SAP) can consistently improve glycemic control [measured as glycated hemoglobin (HbA1c) and time in range (TIR)] while reducing the risk of hypoglycemia. Use of technologies can thereby improve quality of life and reduce the burden of diabetes management compared with self-injection of multiple daily insulin doses (MDI). Novel hybrid closed-loop (HCL) systems represent the latest treatment modality for T1D, combining modern glucose sensors and insulin pumps with a linked control algorithm to offer automated insulin delivery in response to blood glucose levels and trends. HCL systems have been associated with increased TIR, improved HbA1c, and fewer hypoglycemic events compared with CSII, SAP, and MDI, thereby potentially improving quality of life for people with diabetes (PwD) while reducing the costs of treating short- and long-term diabetes-related complications. However, many barriers to their use and regional inequalities remain in Central and Eastern Europe (CEE). Published data suggest that access to diabetes technologies is hindered by lack of funding, underdeveloped health technology assessment (HTA) bodies and guidelines, unfamiliarity with novel therapies, and inadequacies in healthcare system capacities. To optimize the use of diabetes technologies in CEE, an international meeting comprising experts in the field of diabetes was held to map the current regional access, to present the current national reimbursement guidelines, and to recommend solutions to overcome uptake barriers. Recommendations included regional and national development of HTA bodies, efficient allocation of resources, and structured education programs for healthcare professionals and PwD. The responsibility of the healthcare community to ensure that all individuals with T1D gain access to modern technologies in a timely and economically responsible manner, thereby improving health outcomes, was emphasized, particularly for interventions that are cost-effective.

• Jezik: Angleški jezik
• Ključne besede: hybrid closed loop, advanced hybrid closed-loop, type 1 diabetes, Central and Eastern Europe, position statement
• Vrsta gradiva: Članek v reviji
• Tipologija: 1.01 - Izvirni znanstveni članek
• Organizacija: MF - Medicinska fakulteta
• Status publikacije: Objavljeno
• Različica publikacije: Objavljena publikacija
• Leto izida: 2021
• Št. strani: Str. 3107-3135
• Številčenje: Vol. 12, iss. 12
• PID: 20.500.12556/RUL-134828
• UDK: 616.379
• ISSN pri članku: 1869-6961
• DOI: 10.1007/s13300-021-01160-5
• COBISS.SI-ID: 80055043
• Datum objave v RUL: 03.02.2022

Gradivo je del revije

• Naslov: Diabetes therapy
• Skrajšan naslov: Diabetes ther.
• Založnik: Springer Nature
• ISSN: 1869-6961
• COBISS.SI-ID: 520452889

Licence

• Licenca: CC BY-NC 4.0, Creative Commons Priznanje avtorstva-Nekomercialno 4.0 Mednarodna
• Povezava: http://creativecommons.org/licenses/by-nc/4.0/deed.sl
• Opis: Licenca Creative Commons, ki prepoveduje komercialno uporabo, vendar uporabniki ne rabijo upravljati materialnih avtorskih pravic na izpeljanih delih z enako licenco.
• Začetek licenciranja: 25.10.2021

Sekundarni jezik

• Jezik: Slovenski jezik
• Ključne besede: hibridna zaprta zanka, sladkorna bolezen tipa 1, srednja in vzhodna Evropa

Projekti

• Financer: Drugi - Drug financer ali več financerjev
• Program financ.: Medtronic International Trading Sarl